Related Experiment Video
Updated: Oct 9, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Damage of the cardiovascular system in lysosomal storage disease - mucopolysaccharidosis
Sergiy Mykolayovych Pyvovar1, Iuriy Stepanovych Rudyk1, Tetiana Valentynivna Lozyk1
1Government Institution "L.T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine.
Insights
Mucopolysaccharidosis (MPS) frequently causes severe cardiovascular damage, including valve thickening and myocardial hypertrophy, often leading to fatal outcomes. Early detection and treatment are crucial for managing MPS-related heart conditions.
Area of Science:
- Biomedical Science
- Genetics
- Cardiology
Background:
- Mucopolysaccharidoses (MPS) are a group of rare genetic disorders.
- Cardiovascular system involvement is a significant and often fatal complication of MPS.
- Specific MPS types, including Hurler, Hunter, and Maroteaux-Lamy syndromes, exhibit pronounced cardiac pathology.
Purpose of the Study:
- To review and synthesize existing literature on cardiovascular pathologies in mucopolysaccharidosis.
- To highlight the common manifestations and challenges in diagnosing cardiac issues in MPS patients.
- To outline current and emerging therapeutic strategies for cardiovascular complications in MPS.
Main Methods:
- Literature review and analysis of published data on mucopolysaccharidosis and cardiovascular disease.
- Synthesis of findings regarding the types and severity of cardiac damage across different MPS subtypes.
- Examination of diagnostic challenges and treatment modalities.
Main Results:
- Cardiovascular damage is a hallmark of MPS, affecting all types, with severe implications in Hurler, Hunter, and Maroteaux-Lamy syndromes.
- Common findings include valvular thickening and dysfunction, myocardial hypertrophy, conduction abnormalities, coronary artery disease, and hypertension.
- Clinical and functional cardiovascular assessment is complicated by patient physical and intellectual limitations.
Conclusions:
- Cardiovascular pathology is a critical determinant of morbidity and mortality in mucopolysaccharidosis.
- Comprehensive management requires addressing diagnostic difficulties and employing advanced therapies.
- Enzyme replacement therapy and stem cell transplantation show promise for treating cardiovascular complications in MPS.
Abstract:
The analysis of literature data reflecting the issues of the pathology of the cardiovascular system in mucopolysaccharidosis are presented. It was found out that heart and vessels damage is one of the cardinal signs of this pathology, often leading to death. Cardiac pathology is recorded in all types of mucopolysaccharidosis, but it is most significant for patients with three clinical variants of Hurler syndrome, Hunter, and Maroteaux-Lamy syndromes. Typical signs of damage to the cardiovascular system in mucopolysaccharidosis are thickening of the valves with the development of their dysfunction (while the severity of damage to the left-sided valves is more pronounced), myocardial hypertrophy, conduction disturbance, coronary artery disease, arterial hypertension. Many researchers emphasize the difficulties of clinical and functional examination of the cardiovascular system in patients with mucopolysaccharidosis, which is due to the presence of physical and intellectual limitations in patients, ands a gradual increase in symptoms. For the treatment of cardiovascular pathology at mucopolysaccharidosis, medical and surgical methods are used, including enzyme replacement therapy and stem cell transplantation.
Related Concept Videos
Lysosomal Hydrolases
Rheumatic Heart Disease I: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy
Lysosomes
Proteoglycans
Coronary Artery Disease II: Pathophysiology

